Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cyclin D2 | Starlite/ChEMBL | References |
Homo sapiens | cyclin A1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trichomonas vaginalis | cyclin B, putative | cyclin D2 | 289 aa | 246 aa | 21.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | cyclins, putative | 0.0043 | 0.0167 | 0.078 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0043 | 0.0167 | 0.078 |
Trichomonas vaginalis | cyclin B, putative | 0.0073 | 0.2136 | 1 |
Echinococcus granulosus | cyclin B | 0.0073 | 0.2136 | 0.2003 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0073 | 0.2136 | 0.2003 |
Loa Loa (eye worm) | hypothetical protein | 0.0073 | 0.2136 | 0.2003 |
Giardia lamblia | G2/mitotic-specific cyclin B | 0.0073 | 0.2136 | 1 |
Trichomonas vaginalis | cyclins, putative | 0.0073 | 0.2136 | 1 |
Trichomonas vaginalis | cyclin A, putative | 0.0073 | 0.2136 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0073 | 0.2136 | 1 |
Onchocerca volvulus | 0.0073 | 0.2136 | 0.5 | |
Echinococcus multilocularis | G1:S specific cyclin D1 | 0.0193 | 1 | 1 |
Trypanosoma cruzi | cyclin, putative | 0.0073 | 0.2136 | 0.5 |
Plasmodium falciparum | cyclin | 0.0043 | 0.0167 | 0.5 |
Entamoeba histolytica | cyclin, putative | 0.0073 | 0.2136 | 1 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0073 | 0.2136 | 0.2003 |
Loa Loa (eye worm) | hypothetical protein | 0.0073 | 0.2136 | 0.2003 |
Trichomonas vaginalis | cyclins, putative | 0.0073 | 0.2136 | 1 |
Trichomonas vaginalis | cyclin B3, putative | 0.0043 | 0.0167 | 0.078 |
Loa Loa (eye worm) | hypothetical protein | 0.0193 | 1 | 1 |
Leishmania major | CYC2-like cyclin, putative,cyclin 6, putative | 0.0073 | 0.2136 | 0.5 |
Echinococcus multilocularis | cyclin B | 0.0073 | 0.2136 | 0.2003 |
Trypanosoma cruzi | CYC2-like cyclin, putative | 0.0073 | 0.2136 | 0.5 |
Trichomonas vaginalis | cyclin D, putative | 0.0043 | 0.0167 | 0.078 |
Leishmania major | cyclin | 0.0073 | 0.2136 | 0.5 |
Trichomonas vaginalis | cyclins, putative | 0.0073 | 0.2136 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0073 | 0.2136 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0043 | 0.0167 | 0.078 |
Echinococcus granulosus | G1:S specific cyclin D1 | 0.0193 | 1 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0073 | 0.2136 | 1 |
Trichomonas vaginalis | cyclins, putative | 0.0073 | 0.2136 | 1 |
Trypanosoma brucei | mitotic cyclin 6 | 0.0073 | 0.2136 | 0.5 |
Trypanosoma cruzi | cyclin 6, putative | 0.0073 | 0.2136 | 0.5 |
Schistosoma mansoni | cyclin B | 0.0073 | 0.2136 | 0.2003 |
Schistosoma mansoni | cyclin d | 0.0193 | 1 | 1 |
Trypanosoma cruzi | cyclin, putative | 0.0073 | 0.2136 | 0.5 |
Trichomonas vaginalis | cyclin D, putative | 0.0043 | 0.0167 | 0.078 |
Loa Loa (eye worm) | hypothetical protein | 0.0182 | 0.932 | 0.9309 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | 0 uM | Inhibitory concentration was measured by the incorporation of [14C]-thymidine in (human breast carcinoma) MDA-MB-435 (NA=Not Available) | ChEMBL. | 15801831 |
IC50 (binding) | = 1.95 uM | Inhibition of Cyclin-dependent kinase 4-cyclinD | ChEMBL. | 15801831 |
IC50 (binding) | = 1.95 uM | Inhibition of Cyclin-dependent kinase 4-cyclinD | ChEMBL. | 15801831 |
IC50 (binding) | > 5 uM | Inhibition of Cyclin dependent kinase 2-cyclin A | ChEMBL. | 15801831 |
IC50 (binding) | > 5 uM | Inhibition of Cyclin dependent kinase 2-cyclin A | ChEMBL. | 15801831 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.